Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Vistagen
< Previous
1
2
3
Next >
Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
December 17, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Appoints Nick Tressler as Chief Financial Officer
December 01, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
November 26, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
November 13, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
November 10, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Participate in Stifel Healthcare Conference 2025
November 05, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
November 03, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Appoints Paul Edick to its Board of Directors
October 29, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at The Menopause Society 2025 Annual Meeting
October 16, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
September 09, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
August 07, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025
July 31, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at the BTIG Virtual Biotechnology Conference
July 24, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
July 15, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
June 25, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
June 17, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
June 12, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
June 02, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
May 28, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
May 23, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
April 17, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
March 19, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
March 04, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
February 20, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
February 13, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
February 06, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
February 05, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
January 14, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
January 10, 2025
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at the Stifel 2024 Healthcare Conference
November 14, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
